Cash Flow Statement
Growth Metrics

Mimedx (MDXG) Operating Income (2011 - 2026)

Mimedx recorded quarterly Operating Income of -$16.0 million in Q1 2026, down 176.14% quarter-over-quarter from $21.1 million in Q4 2025, and down 294.51% year-over-year from $8.3 million in Q1 2025.

Mimedx's Operating Income history runs 16 years deep, the most recent figure standing at -$16.0 million for Q1 2026.

  • In Q1 2026, Operating Income fell 294.51% year-over-year to -$16.0 million; the TTM figure through Mar 2026 stood at $39.6 million (down 26.58% YoY), while the FY2025 annual figure was $63.9 million, up 8.53% from the prior year.
  • Operating Income came in at -$16.0 million for Q1 2026 at Mimedx, down from $21.1 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $23.4 million in Q2 2024 to a low of -$16.0 million in Q1 2026.
  • A 5-year average of $7.6 million and a median of $11.1 million in 2023 frame the typical range for Operating Income.
  • Across the five-year window, Operating Income slumped 2250.24% in 2022 and surged 3981.76% in 2024, its largest moves.
  • Mimedx's Operating Income stood at $11.3 million in 2022, then surged by 36.95% to $15.5 million in 2023, then slipped by 28.64% to $11.1 million in 2024, then soared by 90.67% to $21.1 million in 2025, then tumbled by 176.14% to -$16.0 million in 2026.
  • According to Business Quant data, Operating Income over the past three periods registered -$16.0 million, $21.1 million, and $22.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.97 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -19.70 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -15.76 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.14 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -3.82 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 642.90 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 268.64 Mn
10 Mimedx 530.69 Mn 370.92 Mn 41.62 Mn -16.05 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -16.05 Mn
Dec 31, 2025 21.08 Mn
Sep 30, 2025 22.19 Mn
Jun 30, 2025 12.37 Mn
Mar 31, 2025 8.25 Mn
Dec 31, 2024 11.05 Mn
Sep 30, 2024 11.16 Mn
Jun 30, 2024 23.45 Mn
Mar 31, 2024 13.20 Mn
Dec 31, 2023 15.49 Mn
Sep 30, 2023 11.12 Mn
Jun 30, 2023 10.84 Mn
Mar 31, 2023 -340,000.00
Dec 31, 2022 11.31 Mn
Sep 30, 2022 -7.10 Mn
Jun 30, 2022 -9.64 Mn
Mar 31, 2022 -9.30 Mn
Dec 31, 2021 1.29 Mn
Sep 30, 2021 -1.08 Mn
Jun 30, 2021 -410,000.00
Mar 31, 2021 -6.85 Mn
Dec 31, 2020 -16.09 Mn
Sep 30, 2020 -9.71 Mn
Jun 30, 2020 -5.86 Mn
Mar 31, 2020 -13.74 Mn
Dec 31, 2019 -4.87 Mn
Sep 30, 2019 14.20 Mn
Jun 30, 2019 -17.07 Mn
Mar 31, 2019 -13.41 Mn
Dec 31, 2018 -8.94 Mn
Sep 30, 2018 373,000.00
Jun 30, 2018 1.68 Mn
Mar 31, 2018 2.97 Mn
Dec 31, 2017 23.98 Mn
Sep 30, 2017 8.84 Mn
Jun 30, 2017 7.21 Mn
Mar 31, 2017 6.19 Mn
Dec 31, 2016 -8.85 Mn
Sep 30, 2016 4.70 Mn
Jun 30, 2016 3.56 Mn
Mar 31, 2016 1.47 Mn
Dec 31, 2015 7.75 Mn
Sep 30, 2015 6.71 Mn
Jun 30, 2015 5.65 Mn
Mar 31, 2015 4.25 Mn
Dec 31, 2014 4.65 Mn
Sep 30, 2014 3.73 Mn
Jun 30, 2014 -392,000.00
Mar 31, 2014 -891,000.00
Dec 31, 2013 -1.41 Mn
Sep 30, 2013 -255,891.00
Jun 30, 2013 -744,217.00
Mar 31, 2013 -226,890.00
Dec 31, 2012 -972,394.00
Sep 30, 2012 -3.63 Mn
Jun 30, 2012 -117,516.00
Mar 31, 2012 -631,365.00
Dec 31, 2011 -2.44 Mn
Sep 30, 2011 -1.65 Mn
Jun 30, 2011 -2.42 Mn
Mar 31, 2011 -3.26 Mn